Literature DB >> 1312970

Characterization of insulinlike growth factor I receptors in human colon cancer.

Y S Guo1, S Narayan, C Yallampalli, P Singh.   

Abstract

A possible role of insulinlike growth factor I (IGF-I) and IGF-I receptors in the proliferation of human colon cancer has, to the best of the authors' knowledge, not been examined as yet. To determine a role of IGF-I in colon cancer, several human colon cancer cell lines and colon cancers were screened for specific binding to 125I-IGF-I. Almost all the human colon cancer cells examined were variably positive for specifically binding 125I-IGF-I. Almost half the colon cancer cell lines examined showed significant growth response to 6.6 nmol/L IGF-I. Dose-dependent growth effects of exogenously added IGF-I (0.05-3.3 nmol/L) were shown in a representative human colon cancer cell line (Colo-205). To determine if IGF-I binding sites on colon cancer cells were similar or different from that described on other cells, the binding affinity, binding specificity, and molecular size of the IGF-I binding sites were characterized in representative human colon cancer cell lines (HCT-116 and Colo-205). The optimal binding assay conditions for measuring maximum number of 125I-IGF-I binding sites on the cells, in vitro, were determined and found to be similar to that described on other cells. Scatchard analysis of the specific binding data showed the presence of a single class of high-affinity binding sites [disassociation constant (Kd) = approximately 1.0-2.0 nmol/L], with a binding capacity of 1.0-2.0 x 10(5) sites per cell. The molecular weight of IGF-I receptors on cell membranes was determined by gel electrophoresis of the affinity cross-linked proteins, followed by autoradiography. A single band of binding proteins with a molecular mass of approximately 300 kilodaltons was evident under nonreducing conditions and separated out into two bands of approximately 240 and approximately 130 kilodaltons under reducing conditions. The 130-kilodalton band represents the alpha subunit of IGF-I receptors, and the 240-kilodalton band may represent aggregates of the receptor subunits that were not reduced completely. The widespread existence of high-affinity binding sites for IGF-I in established human colon cancer cell lines and freshly resected human colon cancers and the proliferative effect of IGF-I in several colon cancer cell lines, in vitro, reflect that IGF-I may be an important endocrine/paracrine/autocrine factor in the growth regulation of colon cancers in situ.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312970

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  40 in total

1.  Colorectal neoplasia in acromegaly.

Authors:  P J Jenkins; G M Besser; P D Fairclough
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

2.  Is diabetes a risk factor for colorectal cancer?

Authors:  Hamed Khalili; Andrew T Chan
Journal:  Dig Dis Sci       Date:  2012-04-25       Impact factor: 3.199

Review 3.  Diabetes mellitus is an independent risk factor for colorectal cancer.

Authors:  Lei Sun; Shiying Yu
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

4.  Visceral Adiposity is a Risk Factor for Poor Prognosis in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy.

Authors:  Chun Seng Lee; David J Murphy; Colm McMahon; Blathnaid Nolan; Garret Cullen; Hugh Mulcahy; Kieran Sheahan; Elizabeth Barnes; David Fennelly; Elizabeth J Ryan; Glen A Doherty
Journal:  J Gastrointest Cancer       Date:  2015-09

Review 5.  The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.

Authors:  M Davies; S Gupta; G Goldspink; M Winslet
Journal:  Int J Colorectal Dis       Date:  2005-06-16       Impact factor: 2.571

Review 6.  Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions.

Authors:  Jeffrey A Meyerhardt
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

7.  Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Authors:  Teresa Troiani; Erika Martinelli; Floriana Morgillo; Anna Capasso; Anna Nappi; Vincenzo Sforza; Fortunato Ciardiello
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

Review 8.  The association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis.

Authors:  Raxitkumar Jinjuvadia; Prateek Lohia; Chetna Jinjuvadia; Sergio Montoya; Suthat Liangpunsakul
Journal:  J Clin Gastroenterol       Date:  2013-01       Impact factor: 3.062

9.  Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors.

Authors:  C S Potten; G Owen; D Hewitt; C A Chadwick; H Hendry; B I Lord; L B Woolford
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

10.  IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer.

Authors:  Gerrit Peters; Silvia Gongoll; Cord Langner; Michael Mengel; Pompiliu Piso; Jürgen Klempnauer; Josef Rüschoff; Hans Kreipe; Reinhard von Wasielewski
Journal:  Virchows Arch       Date:  2003-07-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.